Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Influenza B

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    393 result(s) found for: Influenza B. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-003467-34 Sponsor Protocol Number: FinFLU_HCPimmu_2017THL Start Date*: 2017-10-17
    Sponsor Name:Terveyden ja hyvinvoinnin laitos (THL)
    Full Title: Immune responses to influenza vaccinations and viruses among health care personnel
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022896 10059430 Influenza immunization LLT
    20.0 100000015765 10022001 Influenza (epidemic) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004063-66 Sponsor Protocol Number: V87P2 Start Date*: 2006-10-30
    Sponsor Name:CHIRON
    Full Title: A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD...
    Medical condition: Active influenza profilaxis pandemic strain
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000785-21 Sponsor Protocol Number: GQM11 Start Date*: 2014-07-24
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects
    Medical condition: Prevention of influenza infection in adults from 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001857-29 Sponsor Protocol Number: V130_14 Start Date*: 2019-03-13
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to...
    Medical condition: Prophylaxis of influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-000165-38 Sponsor Protocol Number: V87P1E1 Start Date*: 2007-06-22
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult an...
    Medical condition: Active immunoprofilaxis against potential pandemic influenza strain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003314-16 Sponsor Protocol Number: FLUVALAB-H-15 Start Date*: 2011-08-30
    Sponsor Name:Omninvest Ltd.
    Full Title: A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) In...
    Medical condition: Immunization of healthy people against influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000585-13 Sponsor Protocol Number: MI-CP111 Start Date*: 2004-09-01
    Sponsor Name:MedImmune Vaccines, Inc.
    Full Title: A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6–59 Months of Age
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    3.2 10022000
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) CZ (Completed) ES (Completed) IS (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011529-15 Sponsor Protocol Number: GHB-CS04, VIE-CS-002 Start Date*: 2010-05-26
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: A Phase II Prospective, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Influenza Vaccine GHB11L1 Administered Intranasally Against a Controlled Influenza Virus Cha...
    Medical condition: Prophylaxis of Influenza A (H1N1) infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004721-24 Sponsor Protocol Number: QHD00014 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age
    Medical condition: Prevention of influenza infection in children 6 months through 35 months of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-017781-23 Sponsor Protocol Number: 720903 Start Date*: 2010-01-18
    Sponsor Name:Baxter Innovations GmbH
    Full Title: An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population
    Medical condition: To verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2009/2010 season, manufactured according to the ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004072-19 Sponsor Protocol Number: Acti-INSP-001 Start Date*: 2012-12-28
    Sponsor Name:Vectura GmbH
    Full Title: A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patie...
    Medical condition: Influenza A and B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003170-31 Sponsor Protocol Number: QHD00027 Start Date*: 2021-08-16
    Sponsor Name:Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital
    Full Title: Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting
    Medical condition: Prevention of influenza infection in adults aged 65-79 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003181-34 Sponsor Protocol Number: V70P2 Start Date*: 2006-10-06
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ ve...
    Medical condition: Influenza (vaccine trial)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-003655-74 Sponsor Protocol Number: FluvalAB-H-YL2008 Start Date*: 2008-08-18
    Sponsor Name:Omninvest Ltd.
    Full Title: FluvalAB Seasonal Influenza Vaccine Serologic Clinical Trial for 2008-2009 Influenza Season
    Medical condition: Immunization of healthy people against influenza virus infections.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006307-37 Sponsor Protocol Number: 810601 Start Date*: 2007-05-15
    Sponsor Name:Baxter Innovations GmbH
    Full Title: AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION
    Medical condition: H5N1 Influenza vaccination in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002861-11 Sponsor Protocol Number: FID01C Start Date*: 2007-08-10
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus a...
    Medical condition: prevention, vaccination against Influenza in subjects 65 years or older via intradermal route
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016794 Flu vaccination LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001638-12 Sponsor Protocol Number: mRNA-1010-P302 Start Date*: 2022-09-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older.
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) EE (Completed) BG (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005101-79 Sponsor Protocol Number: GQM04 Start Date*: 2012-10-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects
    Medical condition: Prophylaxis of influenza in subjects from 9-17 years of age (and adults aged 18 to 60 years).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021071-83 Sponsor Protocol Number: FluvalAB-H-YL2010 Start Date*: 2010-08-12
    Sponsor Name:Omninvest Ltd.
    Full Title: Tolerability and Immunogenicity Study of FluvalAB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/strain/0.5 mL) in Adults and Elderly Person
    Medical condition: Immunization of healthy people against influenza virus infections.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012555-22 Sponsor Protocol Number: FluvalAB-H-YL2009 Start Date*: 2009-08-13
    Sponsor Name:Omninvest Ltd.
    Full Title: Serologic Study of FluvalAB Influenza Vaccine (Trivalent, Seasonal) intended to Use in the 2009-2010 Vaccination Season
    Medical condition: Immunization of healthy people against influenza virus infections.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:20:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA